Policy
The $1.2 trillion budget package will now move to the Senate, which is expected to hold a vote next week.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former US Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Imugene Limited announced that prominent City of Hope researchers Yanghee Woo, MD, Associate Clinical Professor, Department of Surgery and Director, Gastroenterology Minimally Invasive Therapy Program, together with Yuman Fong, MD, Professor and Chair of the Department of Surgery, received a AU$564,173 US Department of Defense Grant
CELLINK publishes the quarterly report for the period 1st of June 2019 – 31st of August 2019 and for the full year of operations 2018-2019.
BioArctic and Eisai presented new data regarding BAN2401 at the Alzheimer’s Association International Conference® (AAIC®) in July that confirmed BAN2401’s unique characteristics and was consistent with previously presented results
First academic bridge partnership in Israel aims to translate early-stage research from the Hebrew University (“HU”) of jerusalem into industrial drug development projects
MONROVIA, Calif., October 22, 2019 – AcuraStem, a biotechnology company advancing neuroscience through patient-based drug discovery, announced today that the company has triggered Phase II funding worth $3 million from its Fast Track Small Business Innovation Research grant awarded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health *[Award Number R44NS105156].
Partnership in iABC project will accelerate Alaxia’s development of promising antimicrobial therapy for cystic fibrosis
This morning’s approval from the U.S. Food and Drug Administration marks the 11th therapeutic indication for Botox, a product tent pole for Ireland-based Allergan.
GlaxoSmithKline’s PARP inhibitor Zejula has been approved for wider use in some cancers.
The organizations hope the funding will result in clinical trials in the U.S. and countries in sub-Saharan Africa in the next seven to 10 years. Francis Collins, director of the NIH, said they would focus on “access, scalability and affordability.”
Houston, TX - BreviTest Technologies has been awarded a $1,500,000 grant from the National Institute on Drug Abuse of the National Institutes of Health to further the commercialization of its point-of-care analyzer for rapid opioid urine testing.